Skip to content
Parakho

Valiant Laboratories Ltd

NSE VALIANTLABBSE 543998

Q1 FY27

Revenue
₹115.29 Cr
Profit after tax
₹21.10 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations115.29+146.22%237.47
Other income0.86+31.26%2.32
Total income116.15+144.63%239.79
Employee benefit expense2.60+117.38%7.00
Finance costs1.07+1,354.98%1.90
Depreciation & amortisation2.86+437.19%6.04
Total expenses89.95+99.77%239.02
Profit before tax26.19+969.57%0.77
Tax expense5.09+710.37%4.04
Profit after tax21.10+1,058.93%-3.27
Total comprehensive income21.10+1,058.93%-3.26
Earnings per share
Earnings per share, basic₹3.89₹-0.51
Earnings per share, diluted₹3.89₹-0.51

Q1 FY27 — from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Valiant Laboratories Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 25 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 12 Aug 2026.